Proteomic and metabolomic characterizations of moyamoya disease patient sera
Brain and Behavior · 2023-12 · 13 (12)
DOI: 10.1002/brb3.3328 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain and Behavior, online erschienen am 14.11.2023. Verfasst von Qingbao Guo und 15 weiteren Autor:innen. Beteiligte Einrichtung: Medical School of Chinese PLA, Beijing, China. Hauptthemen laut MEDLINE: Moyamoya Disease. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
The pathogenesis of moyamoya disease (MMD) is unclear. Inflammation and immune imbalance have been identified as potential factors contributing to the occurrence and progression of MMD. However, the specific proteins and metabolites responsible for triggering this process are yet to be established. The purpose of this study is to identify differentially expressed proteins and metabolites in patients with MMD and perform Kyoto Encyclopedia of Genes and Genomes pathway integration analysis to pinpoint crucial proteins and metabolites involved in the disease.
Methods
We performed untargeted metabolomic and data‐independent acquisition proteomic analyses on the serum samples of individuals with MMD and healthy controls (HC).
Results
In patients with MMD versus HC, 24 proteins and 60 metabolites, including 21 anionic metabolites and 39 cationic metabolites, which were significantly different, were identified. In patients with MMD, several proteins involved in inflammation and immune metabolism, such as tubulin beta‐6 and complement C4, were found to have significantly altered levels. Similarly, many metabolites involved in inflammation and immune metabolisms, such as dimethyl 4‐hydroxyisophthalate, beta‐nicotinamide mononucleotide, 2‐(3‐(4‐pyridyl)‐1 H ‐1,2,4‐triazol‐5‐yl)pyridine, and PC (17:1/18:2), were significantly altered. Intriguingly, these proteins and metabolites are involved in the progression of atherosclerosis through immune and inflammatory pathways, although some have never been reported in MMD. Moreover, integrated proteomics and metabolomics studies were conducted to determine shared pathways involving cholesterol metabolism, vitamin digestion, fat digestion, and absorption pathways of proteins and metabolites, which warrant further investigation.
Conclusions
Significant increases in pro‐inflammatory and immunosuppressive abilities have been observed in patients with MMD, accompanied by significant reductions in anti‐inflammatory and immune regulation. Various metabolites and proteins implicated in these processes have been identified for the first time. These findings hold immense significance for comprehending the pathogenesis of MMD and for the development of future drug therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Medical School of Chinese PLA, Beijing, China.
- Department of Neurosurgery, The First Medical Centre, Chinese PLA General Hospital, Beijing, China.
- Department of Neurosurgery, The Fifth Medical Centre, Chinese PLA General Hospital, Beijing, China.
- Department of Neurosurgery, The Eighth Medical Centre, Chinese PLA General Hospital, Beijing, China.
ORCID-Profile: Xiangyang Bao, Lian Duan
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Guo, Q., Wang, Q. N., Li, J., Liu, S., Wang, X., Yu, D., Zou, Z. X., Gao, G., Zhang, Q., Hao, F. B., Feng, J., Yang, R. M., Wang, M., Fu, H., Bao, X., & Duan, L. (2023). Proteomic and metabolomic characterizations of moyamoya disease patient sera. Brain and Behavior, 13(12). https://doi.org/10.1002/brb3.3328
Vancouver
Guo Q, Wang QN, Li J, Liu S, Wang X, Yu D, et al. Proteomic and metabolomic characterizations of moyamoya disease patient sera. Brain and Behavior. 2023;13(12). doi:10.1002/brb3.3328
BibTeX
@article{Guo2023,
author = {Guo, Qingbao and Wang, Qian-Nan and Li, Jingjie and Liu, Simeng and Wang, Xiaopeng and Yu, Dan and Zou, Zheng-Xing and Gao, Gan and Zhang, Qian and Hao, Fang-Bin and Feng, Jie and Yang, Ri-Miao and Wang, Minjie and Fu, Heguan and Bao, Xiangyang and Duan, Lian},
title = {Proteomic and metabolomic characterizations of moyamoya disease patient sera},
journal = {Brain and Behavior},
year = {2023},
volume = {13},
number = {12},
doi = {10.1002/brb3.3328}
}
EUVIMED